Heyuan

People with end stage kidney disease (ESKD) who require dialysis have a much higher risk of developing cardiovascular disease compared to the general population, with heart problems causing over half of the deaths in this group. This trial is studying whether taking low dose aspirin daily can safely reduce cardiovascular events in these dialysis patients. The study is a Phase 4, multi-center, randomized controlled trial designed to provide clear evidence about aspirin's benefits and risks in this specific population, where existing data is limited. Participants will be randomly assigned to receive either a daily 100 mg aspirin tablet or a matching placebo. The trial uses the Chinese peritoneal dialysis and hemodialysis registry to efficiently screen and recruit patients and collect data during routine dialysis care. Follow-up visits occur every six months as part of regular clinical care, and the study will continue until enough cardiovascular events have occurred, expected to take about five years. During the study, participants will have their health monitored through routine clinic visits every six months, with data collected on cardiovascular events and safety. The main outcome measured is the number of participants experiencing major cardiovascular events over the study period. An independent board will oversee safety and study progress. The trial uses intention-to-treat analysis and aims to minimize participant burden by integrating study procedures into usual care.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients who have experienced an acute ischemic stroke. This prospective, multicenter, randomized controlled Phase 4 trial focuses on patients aged 70 years and older who receive treatment within 4.5 hours of stroke onset. The study aims to compare low-dose tenecteplase with the standard dose to understand its impact on stroke recovery in aging patients. Participants are randomly assigned to one of two groups: a low-dose group receiving tenecteplase at 0.175 mg/kg (up to 17.5 mg per patient) or a standard-dose group receiving tenecteplase at 0.25 mg/kg (up to 25 mg per patient). Treatment is administered intravenously as thrombolysis. The trial monitors patients closely to assess how these dosing strategies affect recovery and safety. During the study, researchers will evaluate neurological function using the Modified Rankin Scale 90 days after treatment, measuring the percentage of participants who achieve a score of 0 or 1, indicating no symptoms or no significant disability. Patients will undergo neurological assessments and safety monitoring throughout the trial. The study ensures informed consent and collects relevant clinical data to support its findings on tenecteplase use in elderly stroke patients.

Researchers are evaluating the efficacy and safety of Shuxuening injection as an additional treatment to intravenous thrombolysis in patients with acute ischemic stroke. This multicenter, randomized, double-blind, placebo-controlled phase 3 trial involves patients aged 18 to 100 years who have experienced an ischemic stroke and can be treated within 6 hours of symptom onset. The study aims to improve functional outcomes by reducing brain cell death after stroke using this multi-target neuroprotective agent alongside the standard clot-busting therapy. Participants are randomly assigned in a 1:1 ratio to receive either Shuxuening injection or a placebo. Both groups receive a daily intravenous drip of 20 ml of the study drug or placebo combined with 250 ml of 0.9% sodium chloride injection for 10 to 14 days. The treatment starts as soon as possible after intravenous thrombolysis therapy, and the study compares these two groups to assess differences in recovery and safety. During the trial, researchers will monitor participants for 90 days after randomization. They will assess the primary outcome by measuring the proportion of patients achieving a modified Rankin Scale (mRS) score of 0 to 1, indicating good functional recovery. Safety will be evaluated by tracking adverse events over the same 90-day period. Participants will be closely followed with clinical evaluations to understand the effects and tolerability of Shuxuening injection in stroke recovery.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants (DOACs) early versus later in patients who have acute ischemic stroke related to atrial fibrillation and who have undergone emergency endovascular therapy (EVT). This multicenter, prospective, open-label randomized controlled trial focuses on different timings to begin DOAC therapy to improve outcomes and reduce risks after stroke. Patients will be randomly assigned to one of two groups: the early anticoagulation group, which starts DOACs within four days of symptom onset, and the delayed anticoagulation group, which begins DOACs between 5 and 14 days after symptom onset. The study observes these treatment timings after emergency EVT for stroke, assessing their effects on patient safety and stroke recurrence. Participants will be monitored closely for 90 days after treatment to assess outcomes including recurrent ischemic stroke, symptomatic intracranial hemorrhage, and death from any cause. Evaluations include clinical assessments and imaging such as CT or MRI to detect hemorrhagic changes. Researchers will also review medical history, stroke severity, and treatment adherence. The study involves follow-up visits and data collection to ensure thorough safety and efficacy analysis over the three-month period.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants (DOACs) early versus delaying their start in patients who have had an acute ischemic stroke related to atrial fibrillation and developed bleeding in the brain after emergency endovascular treatment. This is a multicenter, open-label, randomized controlled trial focusing on different timings for beginning DOAC therapy to improve patient outcomes after stroke. Participants are assigned to one of two groups: early anticoagulation, where DOACs are started within 4 weeks after stroke symptoms begin, or delayed anticoagulation, where DOACs are started between 4 to 8 weeks after symptom onset. The study compares these two approaches to understand which timing is safer and more effective in managing stroke patients who experienced hemorrhagic transformation after treatment. During the study, patients will be monitored for a composite outcome including recurrent ischemic stroke, symptomatic brain bleeding, and death from any cause within 90 days. Researchers will conduct assessments and follow patients closely during this period to evaluate the effects of the timing of anticoagulant initiation. Participants will be followed up for 90 days to track these outcomes and assess safety and efficacy.